This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Family-oriented setup guidance to allocate every dollar and align spending with collective priorities.
19,524 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Forward Industries jumped after confirming it expanded its SOL holdings by more than 500,000 coins. Here’s what this ...
As inflation erodes purchasing power, a decades-old rule could push a larger portion of retirement income into taxabl...
As July unfolds, Meta’s AI cloud strategy becomes a potential catalyst for margins and growth. Here’s how today’s act...
NVIDIA unveiled an AI Compute Partnership aimed at financing AI cloud capacity, potentially transforming Nvidia from ...
Anthropic’s Fable returns to service as the U.S. eases export controls, but a cloudy policy framework keeps investors...
Markets just hit fresh highs on AI optimism, but a familiar warning sign is flashing. This time-tested metric foresha...
Beef prices are climbing, and Texas barbecue joints are adjusting menus, portions, and protein options to weather the...
When you’re building a global equity sleeve, two popular choices stand out: Vanguard VT and the SPDR Portfolio Develo...
Income investors are weighing two popular S&P 500 covered-call ETFs. This piece breaks down how SPYI and JEPI generat...
A $29 billion AI-linked stock offering goes live this week, setting up a crucial test of investor appetite for AI pla...
XRP is testing a critical price level in 2026 as regulatory clarity improves and ETF access expands. Analysts debate ...